Equity mutual funds perform differently in different time periods as investment styles and sectors come in and go out of favor.
How To Build A Good Mutual Fund Portfolio
Mutual funds are extremely popular. There must be a reason, right? But, like any other form of investment, mutal fund investing requires some information and resources.
Think Of Virtualization Like A Mutual Fund
John McKnight gave me this analogy, and I can’t be happier about it. It really helps people understand what this “virtualization” thing is all about.
How To Dissect Mutual Fund Returns
While total and compound annual returns are useful, savvy investors will look deeper, using a variety of metrics, to get a more complete picture on mutual fund performance.
Did IBM and Apple Have a Mutual Break-up?
Steve Jobs has accomplished at least one thing recently: all eyes are on his company as industry aficionados give themselves migraines trying to figure out what’s going on over there. So much so, IBM’s new multicore Power PC chips becomes a conversation speed bump serving only to redirect comments toward a confounding Apple business move.
SEC Ordered To Reconsider Mutual Fund Rule
The U.S. Securities and Exchange Commission must now reconsider its rule that says mutual funds have to be overseen by independent chairmen.
Washington Mutual Buys Providian in a $6.45 billion Deal
Washington Mutual announced that it is has entered an agreement to buy Providian Financial in a stock and cash transaction totaling nearly $6.45 billion.
Mutual Fund Expense Lies
When purchasing mutual funds we are cautioned to read the prospectus, look at past performance, check out the fund manager’s record and see what their expense ratios have been.
Mutual Funds: Morningstar Ratings and Fiduciary Grades
Morningstar now provides Fiduciary Grades on mutual funds. How does Morningstar determine these grades? How can mutual fund investors use these grades to better manage their portfolios?
Biotechnology Investing with Mutual Funds and Exchange Traded Funds
Shares of biotechnology companies have declined, after the much anticipated American Society of Clinical Oncologists meeting last week in New Orleans. This sector has been on a roll ever since Genentech (NYSE: DNA) vaulted 45% on May 19, 2003 following positive news from Phase III trials of Avastin in colorectal cancer patients. Is the recent correction a good time to fish or cut-bait?